Paul F. Gores

TL;DR: In this article, the authors found that acute rejection, CsA dosage < 5 mg/kg/day at 1 year, and infection are the major risk factors for the development of chronic rejection.

TL;DR: For recipients on cyclosporine/mycophenolate mofetil/P with no AR at 90 days, the chance of developing subsequent AR is small; if P is tapered and withdrawn, the risk increases, but the majority remain free of acute and chronic rejection.

TL;DR: The overall gain in graft survival rates in the 1980s was principally due to fewer cases of acute rejection and fewer infectious deaths, which indicates that future kidney transplantation research should emphasize prevention of chronic rejection and cardiovascular death.

TL;DR: The novel agent 15-deoxyspergualin, along with antilymphocyte globulin, was used for induction immunosuppression, and azathioprine, prednisone, and cyclosporin for maintenance for maintenance and islet function has been sustained in both patients.

TL;DR: 63 human islet transplants are done, 34 as allografts for patients with type I diabetes and 29 as autograftS after total pancreatectomy to treat chronic pancreatitis in an attempt to simplify endocrine replacement therapy.